Europe PMC requires Javascript to function effectively.
Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please
turn on Javascript support in your web browser and reload this page.
| PMC full text: | - Copyright/LicenseRequest permission to reuse
Copyright © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
| |
Figure 3
TGFBR2 knockout prevents immunophenotypic shifts induced by TGF-β exposure. Post-REP TIL was exposed to 10
ng/mL TGF-β or vehicle for 3days before staining and flow cytometry analysis (n=4TIL donors). TGF-β exposure significantly induced the expression of CD103 in control TIL while repressing expression of BTLA, CD28, CD45RO, LAG-3, and TIM-3. Exposure of TGFBR2-KO TIL (generated using gRNA #3 or gRNA #4) to TGF-β resulted in no change in the expression of these markers, indicating resistance of TGFBR2-KO TIL to phenotypic shifts induced by TGF-β. Data are presented as percent marker positive of live, CD3+CD8+ TIL, and a representative gating hierarchy is presented in online supplemental figure S1. ns, not significant; **, P ≤ 0.01; *** P ≤ 0.001; REP, rapid expansion protocol; TIL, tumor-infiltrating lymphocytes.
Images in this article
Click on the image to see a larger version.